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ABSTRACT
Introduction: An abscopal effect is a clinical observation whereby a local treatment is associated with
regression of metastatic cancer at a site distant from the primary location of treatment. Here, we
describe the clinical systemic effect induced by regional hyperthermia combined with low-dose
chemotherapy and provide immunologic correlates.
Case presentation: A 15-year-old patient had been diagnosed with alveolar rhabdomyosarcoma
(ARMS). All previous treatment options failed in the patient including haploidentical stem cell trans-
plantation and donor lymphocyte infusion. The patient presented with local and metastatic disease,
and upon admission, underwent regional hyperthermia combined with low-dose chemotherapy.
Immediately following therapy severe skin reactions were observed. Skin biopsies revealed an intraepi-
thelial lymphocytic infiltration dominated by CD3þ/CD8þ T cells with a regular network of dendritic
cells. Clinical images compared before and during sequential treatment cycles showed complete meta-
bolic response of the local tumor for more than 10months of therapy. In addition, metastases com-
pletely regressed although they were not direct targets of regional hyperthermia. The systemic effect
was associated with enhanced frequency of NK cells and T cells expressing the lectin-like natural-killer
group 2D activating receptor (NKG2D), an increase of the CD56bright subset of NK cells, as well as an
increase of effector/memory and effector CD8þ and CD4þ T cells in the blood while the percentage of
CD25þFOXP3þ regulatory T cells declined.
Conclusions: Regional hyperthermia combined with low-dose chemotherapy had the potential to cre-
ate a systemic effect which was associated with activation of NK cells and T cells.
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Introduction
Alveolar rhabdomyosarcoma (ARMS) with PAX3–FKHR trans-
location is an aggressive subtype of rhabdomyosarcoma in
childhood with dismal prognosis [1]. Regional hyperthermia
is a noninvasive cancer treatment targeting heat (range
41–43 C) to the region of the localized tumor without an
increase of the systemic body temperature. In a randomized
phase III trial comparing regional hyperthermia combined
with chemotherapy to chemotherapy alone, the addition of
heat improved local tumor control in patients with high-risk
soft tissue sarcoma [2]. After long-term follow-up, survival
was improved also in the subgroup of patients with extrem-
ity tumors who usually die of metastases, suggesting
immune effects outside of the heated target [3]. Cell stress
provides critical cues for activating and targeting the
immune system to recognize cancer cells [4]. Up-regulation
of the MHC class I chain-related protein family (MICA, MICB)
and induction of heat shock protein 70 (HSP70) by heat-
stress have been identified as triggers to activate innate
immunity and to bridge toward adaptive immunity [5]. NK
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cells as well as cytotoxic CD8þ and subsets of CD4þ T cells
express the lectin-like natural-killer group 2D (NKG2D) acti-
vating receptor and thereby can receive co-stimulation
through stress-induced NKG2D ligands, like MICA/B and
HSP70, and thereby support their capacity to kill tumor cells
[6]. Furthermore, NK cells recognize and target cells with an
incomplete or incompatible expression of MHC class I mole-
cules (KIR-ligand mismatch) [7].
Case presentation
A female adolescent received a diagnosis of disseminated
rhabdomyosarcoma in August 2008 at 15 years of age. The
primary tumor originated from the nasal cavity with cervical,
mandibular, and axillary lymph node metastasis, including
pelvic bone with bone marrow involvement. Lymph node
biopsy revealed ARMS with the PAX3–FKHR-translocation.
Standard vincristine, adriamycin, ifosfamide, and actinomycin
D (VAIA) chemotherapy was initiated according to the high-
risk arm of the CWS-IV 2002 protocol with hyper-fractioned
radiotherapy of the primary tumor region and sites of lymph
node involvement. Remission was consolidated by tandem
high-dose thiotepa/cyclophosphamide and melphalan/etopo-
side chemotherapy. In May 2009, because of relapse, the
patient was considered for haploidentical stem-cell trans-
plantation (h-SCT) with her father as an HLA-A2 mismatched
donor. After conditioning, she received a total of
4.90 106/kg CD34þ (CD3/CD19-depleted) cells. The patient
developed grade 4 acute graft-versus-host disease (GvHD)
but remained disease-free for 18months thereafter. Full
donor chimerism was confirmed and no fusion transcript of
the PAX3/FKHR gene was detected by molecular analysis of
the bone marrow aspirate.
In November 2010, the patient developed scleral icterus
and pathological blood chemistry of intrahepatic cholestasis.
The F-18 fluorodeoxyglucose (FDG) PET-CT-scan showed an
abdominal tumor mass of 4 8 cm bi-dimensional diameter.
Metastases were seen in cervical lymph nodes and in the
skeletal system (Figure 1, Panel A). The CT-guided tumor
aspiration specimen revealed desmin-positive tumor cells
consistent with the diagnosis of ARMS. The tumor cells
expressed high levels of CD56 and were negative for PD-L1
(Supplementary Figure S1). In December 2010, she received
a donor lymphocyte infusion (DLI) dosed at 1 x 106 CD3þ/kg
without signs of GvHD. Upon presentation four weeks later,
the FDG PET-CT scan (Figure 1, Panel B) showed disease pro-
gression at all sites and the condition of the patient deterio-
rated (ECOG 3). By ultrasound examination, extensive ascites
fluid formation was diagnosed that required consecutive
draining puncture twice weekly. Response to DLI had not
occurred with apparent continued worsening of disease at
all three sites, appearance of a new bone lesion at the right
extremity and increased size of the lymphadenopathy with
heightened metabolic activity. The clinical situation required
immediate therapeutic intervention. At the end of January
2011, the first cycle of regional hyperthermia was started in
combination with low-dose three-drug chemotherapy based
on the original full-dose regimen (ICE) as previously
published [8]. Regional hyperthermia was performed by the
use of an annular phased array applicator with eight pairs of
microwave antennas surrounding the patient’s abdomen to
focus the heating field to the abdominal tumor (Pyrexar
Company, Salt Lake City, Utah) without increase of systemic
temperature as controlled routinely during treatment.
Regional hyperthermia was applied in accordance with the
safety and quality guidelines of the European Society for
Hyperthermic Oncology [9].
For the first cycle, the patient received ifosfamide
(1.5 g/m2), carboplatin (100mg/m2) and etoposide
(150mg/m2) on day 1 and day 3 (50% reduced dose of the
ICE regimen) combined with regional hyperthermia (60min)
on day 1 and day 3. On day 6, the patient developed severe,
general skin erythema (to the face, trunk, and proximal parts
of both extremities) which was controlled by steroids. Within
three weeks of the first treatment cycle, the patient’s per-
formance improved dramatically with arrest of ascites fluid
formation and complete pain relief, which allowed the
patient to cease pain medication. Because the unexpected
rapid improvement of the patient’s performance was accom-
panied by severe skin reaction at a site outside the heated
area, immune monitoring was initiated after the first cycle. In
February 2011, after the second cycle of regional hyperther-
mia with chemotherapy (ifosfamide (0.75 g/m2), carboplatin
(50mg/m2), and etoposide (75mg/m2) on day 1 and day 3
(25% reduced-dose of the ICE regimen), skin erythema
occurred again and a skin biopsy was taken from the thigh
outside the hyperthermia field. The FDG PET-CT follow-up
scan of March 2011 showed shrinkage of the abdominal
tumor and lower metabolic activity of all metastases. The
previously palpable left cervical nodule was no longer
detectable (Figure 1, Panel C). In June 2011, another dose of
1 106 CD3þ/kg DLI was applied without any GvHD reaction.
The FDG PET-CT of August 2011 (Figure 1, Panel D) docu-
mented no metabolic activity of the abdominal tumor and
no evidence of cervical lymph node involvement and bone
lesions. During the 3- to 4-week intervals between the 5th
and the 11th treatment cycle of regional hyperthermia com-
bined with low-dose chemotherapy, the patient was fully
active, played golf and traveled abroad (ECOG 0). In
November 2011, disease recurrence became clinically evident
and the FDG PET-CT confirmed relapse of an abdominal
tumor with metastases (Figure 1, Panel E). In December
2011, the patient died with chemo-refractory disease. In
total, the patient received 22 regional hyperthermia treat-
ments with 11 low-dose chemotherapy cycles. The dose
intensity (mg/m2/week) over the time-period was 634.9 for
ifosfamide, 42.3 for carboplatin, and 63.5 for etoposide,
respectively.
On presentation in January 2011, routine laboratory ana-
lysis revealed white blood cell counts of 5 109/l before start
of treatment, remaining in the range between 3 109/l and
11 109/l over the course of the 11 treatment cycles. A
steep increase was noticed at the time of relapse due to sep-
tic complications (range 12 109/l to 33 109/l) (Figure
2(A)). The percentage of monocytes was 11% before start of
treatment and showed peak levels before the fourth cycle
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Figure 1. Results of diagnostic imaging throughout the disease course. (A) Whole body metabolic F-18 fluorodeoxyglucose (FDG) PET (maximum intensity projec-
tion, left) and axial CT, PET-CT, and PET (right, from top to bottom) of a cervical and an abdominal cross-section imaging are shown, corresponding to the timeline
showing therapy and disease status. Red circles of the whole body PET indicate the bone metastasis of the right humerus and red circles of the PET on the cervical
cross-section show the metabolic activity of the left lymphadenopathy which is also marked by white and green arrows of the CT and PET-CT. The abdominal
cross-section shows the abdominal tumor mass with high metabolic activity. Panel A (left) represents the status two months before start of treatment with regional
hyperthermia and low-dose chemotherapy. Of note is the high metabolic activity of multiple bone lesions (e.g., scapula, vertebral column, right humerus, pelvis,
sternum, and os sacrum). Panel B shows images 1 month after DLI, when the response to DLI had not occurred, with apparent continued worsening disease at all
three sites, showing progression of the abdominal tumor, the appearance of a new bone lesion at the right extremity, and the increased size of the lymphadenop-
athy with increased metabolic activity before entering treatment. Panel C shows images 12 weeks after two treatment cycles. The heat-targeted abdominal tumor
mass showed a partial response with lower metabolic activity. Furthermore, disease response outside of the hyperthermia field was seen with only minor remaining
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(12%) and the eighth cycle (17%) with a decline (range
0.5–5%) at the time of relapse (Figure 2(B)).
NK cells expressing the activating receptor NKG2D
(CD56þNKG2Dþ) increased sharply during the time of initial
response (5.6-fold increase between second and fifth treatment
cycle) and thereafter started to decline. T cells expressing
NKG2D (CD3þNKG2Dþ) showed a steady increase (2.9-fold)
between treatment cycle 2 and 9 with a peak at the time of
complete response (Figure 3). Among patient NK cells, the
CD56bright NK cell subsets increased significantly in parallel with
Figure 1. (Continued)
activity detectable at the right humerus (red circle) and at the involved left lymph node (CT, white arrow and PET-CT, green arrow). Panel D shows images after
nine treatment cycles with complete response of the abdominal tumor and of distant metastases. Rest of focal activity corresponds to an implanted stent. Panel E
illustrates 2 months after end of the 11th cycle the recurrence of local and distant disease at multiple sites. Enlargements are shown for Panel B (12/2010) at recur-
rent progressive disease and D (08/2011) at complete remission after regional hyperthermia plus low-dose chemotherapy. (B) Schematic drawing of the treatment
course: The numbers (blue) indicate the number of each cycle of low-dose chemotherapy combined with regional hyperthermia. The date of imaging and disease
status is given by the letters A, B, C, D, and E.
Figure 2. (A) White blood cell (WBC) counts (number  109/l) and (B) monocytes given as percentage (%) of WBC counts, of peripheral blood samples taken
before start of regional hyperthermia with low-dose chemotherapy, from 1st to 11th treatment cycles, and during the time of relapse.
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local tumor shrinkage and regression of metastases, represent-
ing more than half of all NK cells and the frequency remained
elevated until the 11th cycle, after which a decline was
observed concurrent with disease relapse (Figure 3(B)). The
CD56brightCD16þ and CD56brightCD16- NK cell subsets showed
similar dynamics (Supplementary Figure S3). To determine the
lytic potential of the NK cells, ex vivo unstimulated and IL-2-
stimulated PBMCs of the patient were tested against K562 tar-
get cells. Cytotoxic activity was deficient but could be restored
by ex vivo stimulation with IL-2 and was higher in the patient
compared to the father who served as a healthy control
(Figure 3(C)). Within the T cell compartment, the frequencies of
CD4þ and CD8þ T cells in patient PBMCs were similar to those
of the father (Figure 3(D)) and remained so at relapse.
Accordingly, the CD4þ/CD8þ ratio was also similar to control
(not shown). The frequencies of terminally differentiated
(Temra) cytotoxic CD8þ (CD45RAþCCR7-) T cells and effector/
memory CD4þ (CD45RACCR7) T cells increased by a factor
of more than 2 (Figure 3(E)) with a reciprocal marked decline
in the numbers of naïve CD8þ and CD4þ (CD45RAþCCR7þ) T
cells. This proportional change remained stable until the 11th
cycle and at relapse without replenishment of the naive T cell
repertoire (Figure 3(F)). Among CD4þ T cells, regulatory T cells
(CD25þFOXP3þ) of the patient were initially elevated but
declined significantly during treatment (Figure 3(G)) and
remained at low levels at relapse.
The two skin biopsies taken at the time of severe skin
reactions after application of regional hyperthermia showed
an intraepithelial lymphocytic infiltration dominated by
CD3þ/CD8þ T cells with a regular network of dendritic cells
(Figure 4). Skin-infiltrating CD56- or granzyme B-positive NK
cells were not detected by immunohistochemistry in the skin
biopsies (data not shown).
Discussion and conclusions
Regional hyperthermia added to chemotherapy has gained
increasing attention as a promising treatment for high-risk
soft tissue sarcoma [10]. Regional hyperthermia affects a
range of cellular targets and processes, including anti-cancer
immunity which might explain consistent prolonged benefits
[11]. In a preclinical model, it was reported that magnet-
mediated hyperthermia alone could exert a strong abscopal
effect against distant non-treated tumors, and could stimu-
late significant endogenous immune responses in sarcoma-
bearing rats, by improving the CD4þ/CD8þ T cell ratio [12].
The results presented in this manuscript describe for the
first time a clinical report of a systemic effect by regional
hyperthermia combined with low-dose chemotherapy associ-
ated with stress-induced immune activation. The patient
described in this case report had received prior chemother-
apy followed by h-SCT and DLI, which resulted in complete
tumor remission and full donor chimerism. After 17months,
in November 2010, tumor recurred at multiple sites and was
refractory to treatment, including DLI given in December
2010. Thus, when admitted to our hospital one month after
DLI, response to DLI had not occurred, with apparent contin-
ued worsening of disease at all three sites, progression of
the abdominal tumor, appearance of a new bone lesion at
the right extremity, and increased size of the lymphadenop-
athy with increased metabolic activity (Figure 1, Panel B).
Thus, her own immune cells and those of the DLI donor, as
well as chemical treatments, had failed to control disease.
While the previous stem cell transplantation (17months
before tumor relapse) had enabled disease control for several
months, the allogeneic immune system obviously was no
longer active against the tumor, hence relapse and progres-
sive disease occurred at the time of new admittance.
Importantly, the most recently applied DLI (given December
2010) could not restart an antitumor process.
After two cycles of regional hyperthermia with low-dose
chemotherapy, the heat-targeted abdominal tumor mass
showed a partial response with lower metabolic activity
(Figure 1, Panel C) and disease response outside of the
hyperthermia field was seen, with only minor remaining
activity detectable at the right humerus and at the involved
left lymph node. This systemic effect already seen after
3months was followed by complete remission 5months later
after nine cycles of regional hyperthermia with low-dose
chemotherapy (Figure 1, Panel D).
Thus, disease progression at admission and disease resist-
ance to DLI (December 2010) was overcome by combined
treatment with regional hyperthermia and chemotherapy.
The patient developed local and systemic clinical responses
and metastases regressed which were not targets of regional
hyperthermia. The disease regression observed at distant
sites is a strong indication that systemic effects were induced
by hyperthermia, similar to reports of abscopal effects
caused by radiation [13]. During the application of regional
hyperthermia, the tumor area reaches temperature around
41.8 C, but the systemic body temperature remained at
37 C. An increase of temperatures at the bone or cervical
lymph node metastases was unlikely. Yet, we cannot rule out
that blood of the heated abdominal region had warmed
neighboring (nonheated) tissues.
It is also unlikely that the remarkable systemic response
of the patient was due to low-dose chemotherapy alone,
since such a rapid onset of the response as observed in this
patient was not seen previously, neither in cases receiving
high-dose ICE alone in chemo-sensitive patients, nor in
chemo-pretreated patients receiving ICE combined with
regional hyperthermia as salvage treatment [8,14]. In the
case presented here, much lower doses and dose intensity of
the ICE regimen were used because of the poor clinical con-
dition of the patient (ECOG 3). Besides their direct cytotoxic
effects, chemotherapeutic agents can stimulate immune
responses either by inducing immunogenic cell death or by
engaging immune effector mechanisms [15]. We speculate
that the dose-reduced regimen of chemotherapy including
ifosfamide contributed to the observed decline of regulatory
T cells. Restoration of effector T cells as well as cytolytic
activity of NK cells has been observed when this immuno-
suppressive T cell subset was depleted by cyclophosphamide
[16]. Whether the reduced numbers of regulatory T cells con-
tributed to the restoration of allo-reactive T cells and the
cytolytic activity of NK cells, as well as the described
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Figure 3. Changes of NKG2D expression on NK and T cells, CD3-CD56bright NK cells, lytic NK cell activity, and frequency of T cell subsets during regional hyperther-
mia and low-dose chemotherapy. PBMCs were collected at different time points during the disease course and used to measure lytic activity and to define cell sub-
set composition by flow cytometry. Respective measurements were also performed with blood samples of the father (control). (A) Increase in frequencies of
NKG2D-expressing cells in patient lymphocytes between the second and fifth treatment cycle. Depicted are CD56/NKG2D and CD3/NKG2D dot plots of lymphocytes
(gated as alive, single, small cells in PBMCs). Numbers in the respective quadrants refer to the percentage positively stained cells. In the CD56/NKG2D dot plot, the
upper right quadrants are CD56þNKG2Dþ cells, which correspond to NKG2Dþ NK cells (3.5% and 19.5%, respectively). Lower right quadrants are CD56þ NKG2D
cells. The lower left quadrants are NKG2DCD56 lymphocytes (B cells and NKG2D T cells). In the CD3/NKG2D dot plot, the upper right quadrant corresponds to
the CD3þNKG2Dþ T cells, which are 11% (second treatment cycle) and 13% (fifth treatment cycle). The quadrants were set according to isotype control stainings.
The dynamics of NKG2D expression on NK cells (CD56þNKG2Dþ) and T cells (CD3þNKG2Dþ) is shown in the bottom graph. The values at each treatment cycle are
the percentages of CD3þNKG2Dþ and CD56þNKG2Dþ cells among gated live lymphocytes. (B) Increase in frequency of CD3-CD56bright NK cells in the patient’s
PBMCs before (closed squares) and after (closed circles) the 2nd, 4th, 5th, 7th, 8th, 9th, 10th, and 11th treatment cycles and at relapse (4th November 2011) in
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induction of primed effector/memory T cells, remains an
open issue. The applied dose of 90mg/m2 of ifosfamide per
day is within the range of metronomic chemotherapy to
cause such effects. Metronomic chemotherapy involves the
frequent administration of conventional chemotherapeutic
agents at low dose. The intention of conventional therapy is
to treat cancer directly by inhibiting or killing rapidly divid-
ing tumor cells whereas metronomic chemotherapy is admin-
istered with the aim of achieving cancer control by evoking
immune-stimulatory properties.
Immunologic changes were observed in the blood, which
included an increase of CD56bright NK cells and T cells
expressing the activating NKG2D receptor. This suggests that
heat-stress delivered essential signals for expansion and
reactivation of these immune cells via the NKG2D receptor
[17]. Evidence for such a scenario is seen in preclinical stud-
ies where NKG2D ligands, like HSP70 and MICA/B, are up-
regulated upon stress conditions [18]. Regulation of MICA/B
through heat-stress is in agreement with the knowledge that
the promotor regions of MIC genes contain heat-shock ele-
ments similar to those found in the human HSP70 promotor
[19]. Furthermore, HSP70 expressed on tumor cells has been
identified to serve as a recognition structure for ex vivo acti-
vated human NK cells expressing NKG2D [20].
In addition, the patient showed increases of primed
effector CD8þ and effector/memory CD4þ T cells early after
treatment initiation indicating that activation of T cells also
occurred. Indeed, the patient showed skewed differentiation
of CD8þ and CD4þ T cells with high frequencies of effector
CD8þ and memory CD4þ T cells concomitant with a defi-
ciency of naive T cells, in particular in the CD4þ T cell
compartment.
The observed skin erythema can be considered as an add-
itional sign of systemic immune activation. Time wise, the
skin erythema occurred directly after regional hyperthermia.
In contrast to the repeated observations of skin reactions fol-
lowing regional hyperthermia combined with low-dose
chemotherapy, neither of the two DLI applications were
associated with typical clinical signs of GvH/GvT or any
changes in immune findings. The lymphocytic infiltrates of
cytotoxic T cells observed in the skin that resembled an
acute GvHD reaction might be interpreted as a clinical bio-
marker for an ongoing T cell activation.
Because of the known history of h-SCT performed
17months earlier, surface expression of killer cell immuno-
globulin receptors (KIR) was analyzed on the patient’s NK
cells. Both patient and donor had an activating KIR haplo-
type B, which has been shown to positively influence out-
comes in leukemias by reducing the risk of relapse [21]. We
assume that the KIR haplotype B may be also beneficial in
solid tumors. Moreover, according to the receptor-ligand mis-
match, we could detect potentially alloreactive donor-derived
NK cells in the patient post-transplant. Those cells expressed
only the CD158b receptor (KIR1DL2/KIRDL3) but not CD158a
(KIR2DL1) or CD158e (KIR3DL1) receptors. Since the patient
had HLA-C alleles belonging to the Cw2 group, which are no
cognate ligands for the CD158b receptor, the NK cell subset
should not be inhibited. Thus, part of the heat-stress induced
immunity could be mediated by NK cells with the potential
for allo-reactivity [22]. Indeed, sporadic cases of pediatric
malignancy have been treated using h-SCT alone or followed
by DLI with the aim of exerting a graft-vs-tumor effect
[23,24]. In contrast, our patient had disease progression after
DLI when she was considered to receive regional hyperther-
mia combined with low-dose chemotherapy. Thus, the NK
cells of this patient were obviously inactive or exhausted at
this stage of disease. This is consistent with our previous
results in chemo-pretreated patients with high-risk soft tissue
sarcoma who showed downregulation of NKG2D-expressing
NK cells accompanied with decreased cytotoxic activity [25].
Treatment with regional hyperthermia may have functionally
activated patient NK cells and CD56bright NK cells, which
increased continuously with each treatment cycle. These cells
may have also contributed to an antitumor response.
Supportive of an NK-associated mechanism of antitumor
response is the observation that the patient’s tumor cells
Figure 3. (Continued)
comparison to PBMCs of the father at different time points (open diamonds). The values are the percentages of all CD56bright NK cells within the NK cell population
(without discrimination according to CD16 expression), gated as CD3CD56þ lymphocytes. The increase of CD3CD56bright NK cells over the disease course was
statistically significant (p¼ 0.031) considering the values measured before each treatment cycle. For details concerning the flow cytometry and statistics see
Supplementary Appendix. (C) Upper panel: lytic activity of ex vivo IL-2-stimulated (red) and unstimulated (blue) PBMCs of the patient (before the fourth treatment
cycle) against K562 cells at effector (PBMC) to target (K562) ratios of 10:1 to 0.3:1, as determined by a standard 4-h Europium assay. Lower panel: Lytic activity of ex
vivo IL-2-stimulated PBMCs of the patient (before the fourth treatment cycle, red) and the father (control, blue) against K562 cells at effector (PBMC) to target
(K562) ratios of 10:1 to 0.3:1, as determined by a standard 4-h Europium assay. Mean values of triplicates are shown in the experiment. The specific lysis is calcu-
lated according to the equation: (experimental release – spontaneous release)/(maximum release – spontaneous release) x 100. For technical details see
Supplementary Appendix. (D) CD4þ and CD8þ T cell frequencies in PBMCs taken before (closed squares) and after (closed circles) the 4th, 5th, 7th, 8th, 9th, 10th,
and 11th treatment cycles and at relapse (4th November 2011) in comparison to PBMCs of the father (control) at different time points (open diamonds). The fre-
quencies were determined by flow cytometry after gating on live, single CD3þ T cells. For technical details see Supplementary Appendix. (E) Change in frequencies
of CD4þ T effector/memory (Teff/em) and terminally differentiated CD8þ T cells (Temra) and (F) Change in frequency of naive CD4þ and CD8þ T cells
(CD45RAþCCR7þ) in patient PBMCs before (squares) and after (circles) the 5th, 7th, 8th, 9th, 10th and 11th treatment cycles, and at relapse (4th November 2011)
compared to father (control). PCMCs were stained with antibodies to CD3, CD4, CD8 CD45RA and CCR7. The CD3þ T cells were selected and subdivided for CD4þ
and CD8þ T cells, which were then subcategorized according to the markers CD45RA and CCR7 in naïve (CD45RAþCCR7þ), effector/memory (Teff/em,
CD45RACCR7), central memory (Tcm, CD45RACCR7þ) and terminally differentiated cytotoxic T cells (Temra, CD45RAþCCR7) (for details see Supplementary
Appendix). Temra are mostly found in the CD8þ T cell population and represent those with a cytotoxic differentiation status. (G) Decline in frequencies of
CD25þFOXP3þ regulatory T cells (Treg cells) during treatment course, including the time point at relapse. PBMCs were stained with antibodies to detect CD3, CD4,
CD25 and FOXP3, the later following cell permeabilization. The frequency of CD25þFOXP3þ Treg cells was determined among the CD4þ T cells by gating on live
CD3þCD4þ lymphocytes. Depicted are the percentages of CD25þFOXP3þ Treg of the patient PBMCs harvested before the indicated treatment cycle (black squares)
and the father’s PBMCs at different time points. The decline overs disease course was statistically significant (p¼ 0.031). For technical details regarding flow cytome-
try and statistics see Supplementary Appendix.
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aberrantly expressed CD56, also known as neural cell adhe-
sion molecule-1 (NCAM-1). Aberrant CD56 expression is a
common finding for rhabdomyosarcoma, including ARMS
[26], and a recent study indicates an association between
tumor-cell expression of CD56 and sensitivity to NK-cell-
mediated killing in breast cancer [27].
Soluble MIC, shredded by tumor cells, is capable of bind-
ing the NKG2D receptor on NK and T cells and, in conse-
quence, the receptor is internalized and no longer present
for T and NK cell activation [28,29]. Therefore, ligand shed-
ding by tumor cells is a powerful way to overcome NKG2D-
mediated immune surveillance which might explain why
treatment eventually failed the patient.
An alternative reason for final treatment failure could be
the accumulation of activated effector and memory T cells
without simultaneous replenishment of the naive T cell rep-
ertoire which occurred concurrent with control of disease.
Indeed, an unlimited consumption of naive T cells can lead
to loss of immune control, a situation that is observed in
persistent infection [30]. The reduced frequencies of naïve
CD4þ and CD8þ T cells could be a direct result of ifosfamide
administration even at low-dose, which has been shown to
block T cell proliferation and their functional activity whereas
NK cells were not substantially affected [31]. To avoid the
unlimited consumption of naïve T cells, it might be reason-
able to use DLI during the treatment of regional
Figure 4. Immunohistochemical analysis of lymphocytic infiltrates in the skin biopsies. H&E sections of the skin biopsy taken in February 2011 (A, 200-fold) and
November 2011 (B, 200-fold) are shown. After regional hyperthermia concurrent with the skin erythema, a chronic interface dermatitis with focal epithelial lympho-
cytic infiltrates was found in both biopsies. The magnified image (C, 630-fold) revealed epidermal spongiosis, vacuolization of basal cell layers, and dyskeratotic ker-
atinocytes with few apoptotic bodies. The immunohistochemistry showed an infiltration by CD3þ T-lymphocytes (D) which consisted predominately of CD8þ
cytotoxic T lymphocytes (E) and fewer CD4þ T helper cells (F).
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Figure 5. (A) Working hypothesis of (heat) stress-induced immune activation. CD56bright NK cells expressing the NKG2D activating receptor interact with
MICA/B and HSP70 that are co-induced on tumor cells by regional hyperthermia. Activated CD56bright NK cells have the capacity to lyse tumor cells directly
[18,20,37–39]. CD56bright NK cells secret IFN-c and thereby promote the activation of CD4þ helper T cells. CD4þ helper T cells recognize tumor peptides pre-
sented by MHC class II molecules on DCs and thereby can stimulate the CTL response of CD4þ effector/memory T cells (modified from Ref. [7]). Alternatively,
HSP70-chaperoned tumor peptides (HSP70-peptide complexes ) released from the dying tumor (immunogenic cell death through hyperthermia) are taken up
by DCs. Cross-presentation of peptides by MHC class I molecules on DCs then stimulate the response of CD8þ cytotoxic T cells [37,38]. Low-dose chemotherapy is
able to kill Treg cells, thereby, blocking the immunosuppressive effects of Treg cells on the CTL response [16]. (B) Despite the setting of HLA haplotype-mismatched
HSCT, where NK cells are not inhibited by KIR/HLA class I interactions, tumor cell killing does not occur if the tumor cells lack activating ligands (MICA, HSP70) for
the NK cell-expressed activating receptor NKG2D and if Tregs are present (modified from Refs. [7,22]). The capacity of allogeneic cytotoxicity of NK cells can be
restored by hyperthermia which is known to induce MICA/B and HSP70 expression on the tumor cells. This provides the signals for the NKG2D activating receptor
expressed on NK cells [18]. Low-dose chemotherapy is able to kill Treg cells, thereby blocking the immunosuppressive effects of Treg cells on the allogeneic NK
activity [16]. Abbreviations: CTL: cytotoxic T cell; DC: dendritic cell; HLA: human leukocyte antigen; HSP: heat shock protein; HSCT: hematopoietic stem cell trans-
plantation; IFN-c: interferon gamma; KIR: killer immunoglobulin-like receptor; MIC or MIC: MHC class I chain-related protein family; MHC: major histocompatibility
complex; NK: natural killer; NKG2D: natural killer group 2D; Treg: regulatory T cells.
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hyperthermia and chemotherapy in the setting of future tri-
als. DLI has been already shown to efficiently reverse CD8þ T
cell exhaustion [32]. The observed higher frequencies of
monocytes before start of treatment, the peak levels at the
time of response, and the decline at the time of relapse are
in line with a recent study identifying the number of classical
monocytes in the peripheral blood as a potential biomarker
for response to anti-PD-1 immunotherapy [33]. Despite
ongoing immune activation in the blood, solid tumors can
build up local immune evasion mechanisms that inhibit T
and NK cell activity through the induction of immune inhibi-
tory pathway, such PD-1/PD-L1 [34], or prevent immune cells
from infiltrating the tumor milieu [35].
In summary, we present a clinical case study of a patient
at end stage of disease where the immune system had failed
to control disease progression. The observed systemic effect
with disease regression at distant sites associated with restor-
ation of NK cell activity and priming of T cells are suggestive
for stress-related immune-effects induced by local hyperther-
mia treatment combined with low-dose chemotherapy in
this patient. A schematic diagram illustrates the hypothetical
mechanisms of action based on published preclinical reports
and the results as discussed (Figure 5). An ongoing phase II
randomized clinical trial is prospectively validating the poten-
tial of regional hyperthermia combined with chemotherapy
to induce immunity against distant metastases [36].
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